Mirai Bio lures Bayer exec to be its president and COO

20 November 2024

Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO).

A Flagship Pioneering company, Mirai Bio launched in September 2024 as the first open end-to-end platform for genetic medicines.

As a global leader in all aspects of biopharmaceutical development, platform innovation, and end-to-end technical operations, Dr Vogel will guide the company’s growth and platform development as it expands partnerships with companies across the biotech industry who are seeking to develop novel genetic medicines, says Mirai.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK